FDA approves Teva’s Proair
WASHINGTON The Food and Drug Administration announced Tuesday that it had approved Teva’s Proair HFA inhalation aerosol.
The drug is approved for treating or preventing asthma-related bronchospasm with reversible obstructive airway disease in patients aged 4 to 11 and for the prevention of exercise-induced bronchospasm in patients of the same age.
Bayer denies takeover rumors
FRANKFURT, Germany Reports of Bayer’s imminent takeover appear greatly exaggerated.
The company’s chief executive officer told a German newspaper that it would not be taken over, amid rumors last week that Pfizer sought to acquire it. But Bayer has a number of drugs in its research pipeline, while many of Pfizer’s blockbuster drugs will soon go off patent, facing competition from generic drug makers.
MyMedSchedule now available to the public
INDIANAPOLIS A service that helps people with organ transplants manage their medication schedules has become available to the public.
MyMedSchedule used to be available only in hospitals, reminding organ transplant recipients to take their medications and helping them avoid errors. People who have received transplants often must take several drugs to avoid rejection of the new organs.
Companies such as Community Health Network and the American Society of Health-System Pharmacists offer similar services.